EUROGIN.COM
PRELIMINARY PROGRAM
WEDNESDAY,
MARCH
18
SCIENTIFIC SESSIONS 8.30 • 10.00 HPV SCREENING IN TRANSGENDER INDIVIDUALS – WHO, WHY, HOW, AND WHAT TO DO WITH THE RESULT CHAIR: H. Milerad (Sweden) • T. J. Palmer (UK) • K. Sundström (Sweden) With increasing acceptance of transgender individuals in society, the particular health problems that they pose need to be recognized and managed. One of these problems is HPV infection and its consequences in transgender individuals who still have a cervix and vagina, and in transgender individuals with a neo-vagina. This session aims to set out how finding, assessing and treating HPV infections is managed within existing health care programs and then to discuss the ways in which transgender individuals can be approached, screened and managed.
10.30 • 12.30 HPV POINT OF CARE TESTS – HARNESSING THE EFFORTS OF THE WIDER MOLECULAR DIAGNOSTICS COMMUNITY TO EFFECT REAL CHANGE CHAIR: K. Cuschieri (UK) • M. Poljak (Slovenia) Robust point of care HPV tests will be critical for the fulfilment of HPV elimination goals. Arguably we have not engaged the full breadth of international molecular diagnostic expertise to support their development. To address this, in this two-part session we will • Assess the development and implementation of POC tests using targets other than HPV, reflecting on what we can - and should - learn • Hear from early career researchers regarding the challenges of developing an HPV POC and how the EUROGIN community can support • Gain updates from technology experts on extraction and amplification systems designed specifically to support POC tests • Hear from those directly involved in the development and application of novel POC tests including HPV POC tests
12.00 • 13.30 GLOBAL HPV LABORATORY NETWORK: STRENGTHENING HPV LABORATORY CAPACITY FOR CERVICAL CANCER ELIMINATION CHAIR: L. S. Arroyo Mühr (Sweden) • E. Padalko (Belgium) This session brings together leading experts to present recent advances and strategic developments in global HPV laboratory networks. The focus will be on the evolving needs from WHO, innovations in assay evaluation and sample adequacy, and the implementation of laboratory support and training in new regions.
-1 -